Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN EBITDA Margin
EBITDA as a percentage of revenue.
Amarin Corporation plcNASDAQ: AMRN
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -26.9%
EBITDA Margin was -26.9% in Q1 FY2026, up 3.8 pp from a year earlier. On a trailing-twelve-month basis it was -2.4%, up 29.0 pp year over year. Over 3 fiscal years it widened by 11.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -11.4% for the fiscal year ending Dec 2026, up from -15.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -26.9%-26.6 pp QoQ
- Last fiscal yearDec 2025
- -15.5%+17.0 pp YoY
- LTMMar 2026
- -2.4%+29.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.8 pp | -9.4 pp | -13.1 pp |
| 1 year | +17.0 pp | +4.0 pp | -13.0 pp |
| 3 years | +11.8 pp | +7.0 pp | -4.8 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -15.5%
- Year-over-year change
- +17.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -15.5% | +17.0pp |
| FY2024 | 2024-12-31 | -32.4% | -15.9pp |
| FY2023 | 2023-12-31 | -16.5% | +10.8pp |
| FY2022 | 2022-12-31 | -27.3% | -29.7pp |
| FY2021 | 2021-12-31 | 2.4% | — |
EBITDA Margin vs competitors
How AMRN compares with its peers on the latest reported figures
- AMRN's LTM Mar 2026 EBITDA Margin of -2.4% is the highest of the 7 companies compared; the peer median is -5256.3%.
- Its year-over-year change of +29.0 pp is the 2nd highest of 6, against a peer median of -137.9 pp.
- Over three fiscal years its change of +11.8 pp compares with a peer median of -15524.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -2.4% | +29.0 pp | +11.8 pp | |
| LTM Mar 2026 | -75.1% | -6.9 pp | +343.8 pp | |
| LTM Mar 2026 | -1740.8% | -1565.2 pp | -167.5 pp | |
| LTM Mar 2026 | -2034.0% | -137.9 pp | — | |
| LTM Mar 2026 | -8478.5% | — | -15524.4 pp | |
| LTM Mar 2026 | -245200.0% | +208560.0 pp | -336389.4 pp | |
| LTM Mar 2026 | -770932.3% | -482924.6 pp | -730107.8 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ENGNenGene Holdings Inc. | FY2025 | — | — | — |
| Peer median (excluding AMRN) | -5256.3% | -137.9 pp | -15524.4 pp | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 583.19M | 369.19M | 306.91M | 228.61M | 213.65M |
| Cost of Revenue | 121.33M | 126.71M | 141.37M | 147.23M | 92.78M |
| Gross Profit | 461.86M | 242.48M | 165.54M | 81.38M | 120.87M |
| Gross Margin | 79.2% | 65.7% | 53.9% | 35.6% | 56.6% |
| Research & Development | 29.31M | 30.41M | 22.22M | 20.87M | 19.81M |
| Selling, General & Admin | 408.33M | 304.42M | 199.94M | 152.31M | 115M |
| Operating Expenses | 451.36M | 348.35M | 222.16M | 173.18M | 134.81M |
| Depreciation & Amortization | 2.86M | 3.1M | 2.97M | 3.01M | 3.03M |
| EBITDA | 14.28M | (100.69M) | (50.7M) | (74.18M) | (33.01M) |
| EBITDA Margin | 2.4% | -27.3% | -16.5% | -32.4% | -15.5% |
| Operating Income | 10.5M | (105.87M) | (56.62M) | (91.8M) | (13.94M) |
| Operating Margin | 1.8% | -28.7% | -18.4% | -40.2% | -6.5% |
| Interest Income | 1.22M | 2.82M | 11.86M | 13.4M | 10.85M |
| Interest Expense | 129K | 15K | 8K | 7K | 7K |
| Other Income / Expenses | 789K | 2.06M | 2.95M | 14.6M | (22.11M) |
| Income Before Tax | 11.29M | (103.81M) | (53.67M) | (77.2M) | (36.05M) |
| Pre-Tax Margin | 1.9% | -28.1% | -17.5% | -33.8% | -16.9% |
| Income Tax Expense | 3.56M | 2M | 5.44M | 4.98M | 2.75M |
| Net Income | 7.73M | (105.8M) | (59.11M) | (82.18M) | (38.8M) |
| Net Margin | 1.3% | -28.7% | -19.3% | -35.9% | -18.2% |
| EPS (Basic) | 0.39 | (5.20) | (3.00) | (4.00) | (1.80) |
| EPS (Diluted) | 0.38 | (5.20) | (3.00) | (4.00) | (1.80) |
| Weighted Avg Shares | 19.8M | 20.06M | 19.7M | 20.55M | 20.75M |
| Weighted Avg Shares (Diluted) | 20.12M | 20.06M | 20.38M | 20.55M | 20.75M |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.